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Background: Acquisition of Pseudomonas aeruginosa (Psa) and infection with mucoid strains is associated with repeated pulmonary exacerbations
which often require intravenous and long-term nebulised antibiotic treatments, repeated hospitalizations and leads to a more precipitous decline in
lung function. Anti-Psa antibiotic therapy early in the course of Psa infection in patients with cystic fibrosis (CF) may result in eradication of Psa
and prevention or delay of colonization with the organism. From January 1995 to December 2009 our paediatric CF clinic has followed an early
eradication protocol for the first appearance of Psa. In this paper we report on the economic effects after 15 years as reflected in hospitalization and
antibiotic usage and cost.
Methods: The Psa-eradication protocol includes 2 weeks of IV piperacillin and tobramycin, followed by oral ciprofloxacin for 3 weeks, and
nebulised colistimethate for 6 months. The same protocol is used for newly diagnosed CF patients who grow Psa on their first visit or who grow a
mucoid strain, multiresistant strain of Psa or whose Psa co-cultured with Burkholderia cepacia complex, and for patients in whom Psa recurs after
initial clearance.
Results: 195 Psa eradication courses were completed from 1995 to 2009 with an overall Psa clearance rate of 90%. Patients that only cultured a
Psa classic (non-mucoid) strain had a clearance rate was 96.5%. The percentage of children chronically infected with Psa has declined from 44%
in 1994 to 15% in 2009.Total days spent in hospital for all reasons declined by 43%; chronic Psa hospital days declined by 75%; IV and nebulised
anti-Psa antibiotic costs reduced by 44%.
Conclusions: Results indicate that application of a Pseudomonas eradication protocol as described in this report has economic and resource
utilization benefits in addition to clinical benefits.
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Pseudomonas aeruginosa (Psa) is the predominant pathogen
affecting patients with cystic fibrosis (CF) [1]. Cystic fibrosis
patients infected with Psa have increased pulmonary disease
and experience more rapid decline in pulmonary function than
patients who are Psa culture and antibody negative [2–6].⁎ Corresponding author at: Cystic Fibrosis Clinic, BC Children's Hospital,
4480 Oak Street, Vancouver, BC, Canada V6H3V4. Tel.: +1 604 875 2146;
fax: +1 604 875 2349.
E-mail address: ylillquist@cw.bc.ca (Y.P. Lillquist).
1569-1993/$ - see front matter © 2011 European Cystic Fibrosis Society. Publishe
doi:10.1016/j.jcf.2011.01.002Acquisition of Psa and subsequent chronic infection with
mucoid strains result in repeated pulmonary exacerbations,
which often require intensive intravenous (IV) and long term
nebulised antibiotic treatments, repeated hospitalizations and
despite these interventions, are likely to have a more precipitous
decline in lung function over time.
Since the initial report by Littlewood et al. [7] evidence
suggests that anti-Pseudomonas antibiotic therapy early in the
course of Psa infection may prevent or delay chronic infection.
Several early eradication protocols and randomized clinical
trials report a delay in chronic infection with Psa and in some
cases achieved eradication [7–13].d by Elsevier B.V. All rights reserved.
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eradication protocol for initial appearance of Psa. Successful
implementation of this protocol has required a paradigm shift
from symptom-triggered treatment to microbial culture-based
pre-symptomatic therapy, and “buy-in” from patients and clinic
staff alike; having a significant impact on our clinic. In this
paper we report the economic effects of this protocol after
15 years of implementation, as reflected by hospitalization and
antibiotic usage and cost.
2. Patients and methods
CF patients ages newborn to 18 years (demographics for
patient cohorts in 1994, 2000, 2005, 2008 and 2009 shown in
Table 1) attend the CF outpatient clinic every 3–4 months, or
more frequently if clinically indicated. Sputum, or throat culture
if sputum is not produced, is taken at every clinic visit in
conjunction with airway clearance, performed under the
supervision of a CF physiotherapist. Growth and nutritional
parameters are recorded and reviewed by the CF clinic dietician.
Pulmonary function testing is performed at each visit in all
children ≥6 years of age.
The protocol includes:
• 2 weeks of IV piperacillin (600 mg/kg/day divided q6h) and
tobramycin (12 mg/kg/day divided q8h)
• followed by oral ciprofloxacin (30 mg/kg/day) for 3 weeks
• and nebulised colistimethate (100 mg of colistin base bid) for
6 months.
IV access over the 2-week course is secured by the insertion
of a midline or PICC line. Tobramycin peak and trough serum
levels are checked after the third dose, and then weekly to
ensure that optimal therapeutic and non-toxic drug levels are
achieved. Aminoglycoside ototoxicity and nephrotoxicity are
monitored through audiology and renal function testing (serum
creatinine and nuclear GFR). Sputum, or a throat culture if the
patient is non-productive, is obtained at the start of treatment,
weekly while receiving IV antibiotics, one month after
completion of the IV course, and thereafter at regular 3-
monthly CF clinic visits. Physiotherapy technique is reviewed
and treatments are maintained three times daily. Nutritional
support is optimized and daily IV lipids administered while the
patient is on IV antibiotics, in addition to a high calorie, highTable 1
Clinic patient demographic data by age cohort.
Age cohort 1994 2000 2005 2008 2009
0–6 yr 45 37 47 29 34
7–12 yr 44 45 39 41 45
13–18 yr 41 48 61 54 44
Total # of clinic patients M/F 130
68/62
130
70/60
147
72/75
124
69/55
123
68/55
# of Psa eradication
treatments/year
None 10 12 23 10protein diet plus pancreatic enzymes. Although it is technically
possible to carry out this regimen at home, the cost and limited
access to home IV services, coupled with difficulties in
monitoring patients at home given the large geographic area
served by the clinic (approximately 364,800 sq. miles), limited
family time available when both parents work outside the home,
and perceived benefits of intensive review and physiotherapy
supervision by clinic staff in hospital has meant that 189 of the
195 (97%) IV courses were given in hospital followed by
administration of oral and nebulised antibiotics at home.
Newly diagnosed CF patients who grew Psa on their first
clinic visit (n=11) were also treated with this eradication
protocol, in addition to 6 patients who grew a mucoid strain at
their first appearance of Psa, and 9 patients whose initial
cultures either grew a multi-resistant strain of Psa, or whose Psa
co-cultured with Burkholderia cepacia complex. The same
protocol is repeated for patients in whom Psa recurred at a later
time after their initial clearance of Psa (n=75). Overall results
include all of these patients. Clearance of Psa is defined as 3
negative consecutive cultures for Psa over a 6 month period
with a minimum interval of 3 months between cultures. Chronic
infection is defined as more than 50% of cultures being Psa
positive in the preceding year (Leeds criteria) [15,16].
Inpatient and outpatient antibiotic costs of anti-Pseudomonas
IV and nebulised medications were obtained annually through
analysis of pharmacy records. Hospital patient days for
pulmonary exacerbations with Pseudomonas infection and
Pseudomonas eradication protocols were obtained from retro-
spective review of hospital records. Hospital per diem cost was
calculated using 1994 rates and for comparison purposes was not
adjusted for inflation.
3. Results
3.1. Efficacy
A total of 195 Psa eradication courses have been
completed during the period from January 1995 to December
2009, with an overall Psa clearance success rate of 90%.
When only Psa classic (non-mucoid strain) was cultured
(n=87), the clearance rate was 96.5%. As a result of this
intervention the percentage of all clinic patients chronically
infected with Psa has declined from 44% in 1994 to 29% in
2000, 18% in 2005, 14% in 2008 and 15% in 2009 (Fig. 1).
The mean age at first culture of Psa was 7 years (range
6 months to 16 years of age). The number of Psa eradication
courses per year is shown in Table 1.
Of the 195 Psa eradication treatment courses, 176 were Psa
culture negative after completion of the antibiotic course. Cultures
were monitored a minimum of every 3 months for up to
150 months (12.5 years). When expressed as median time to
recurrence (Kaplan–Meier plot), the T½was30 months (T½=the
time at which half of the treated patients showed a re-growth of
Psa) (Fig. 2) [18]. 30% re-cultured Psa after a median interval of
18 months (range 11 to 72 months). Some patients remain Psa
negative on follow up for up to 150 months. After intensive Psa
treatment protocol, surveillance for the presence of other
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Fig. 2. Kaplan–Meier plot of time to recurrence of Pseudomonas aeruginosa [18].
Fig. 1. Percent chronic Pseudomonas aeruginosa infection rate by age cohort.
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of Psa (Fig. 3) when reviewed retrospectively for up to 7 years
[19]. Pulmonary function (FEV1 % predicted) decline per year is
less precipitous in patients who are Psa negative (−0.63%
predicted/yr) compared to those chronically infected with Psa
(−1.31% predicted/yr) (Fig. 4) [18].Organism 
1 yr pre-
treatment 
n=31 patients 
1 yr pre-
(160 c
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S. maltophilia 
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Fig. 3. Surveillance of other organisms 1 yr p3.2. Safety
No serious adverse events occurred as a result of this
treatment protocol. Four patients developed skin sensitivity
reactions which subsided upon substitution of meropenem for
piperacillin. No significant renal function abnormalities weretreatment 
ultures) 
Isolate at time of 
Psa appearance 
(49 cultures) 
Post-treatment 
(531 cultures) 
Psa only 29%  
 of all 
ures 
57% of all 
cultures 
62% of all 
cultures 
0 14 18 
0 8 6 
5 6 4 
1 6 3 
1 0 1 
1 0 1 
1 1 1 
0 0 <1 
0 0 <1 
re-Psa treatment and post treatment [19].
Fig. 4. Effect of Psa on annual decline in pulmonary function (FEV1 % predicted) for 2007.
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aminoglycoside exposure. These results have recently been
analysed and reported for the period January 2006 to May 2009
using 99mTc-DPTA nuclear GFR, annual urinalysis, and serum
creatinine and urea measurements [14]. No resistant strains of
Psa emerged as a result of treatment.
3.3. Cost benefit
Since instituting this early eradication protocol, the decreas-
ing number of CF patients chronically infected with Psa has had
an impact on hospital admissions, days in hospital (Table 2) and
use of anti-pseudomonal antibiotics (Table 3). Although criteriaTable 2
1994 vs. 2009 Comparison of patients chronically infected with Pseudomonas and
Year % of clinic patients chronically
infected with Pseudomonas
aeruginosa
Hospital days for patients with
chronic Pseudomonas
(% of total hospital days)
1994 44 990 (56%)
2000 29 980 (53%)
2005 18 550 (43%)
2008 14 290 (26%)
2009 15 241 (24%)
Table 3
Cost of intravenous and nebulised anti-Pseudomonas antibiotics.
Year $ IV anti-Psa antibiotics
for chronic Psa and
eradication treatment
protocols
$ Nebulised antibiotics
for chronic Psa
In hospital At home
1994 $94,000 $39,000 $600,000
2009 $40,000 $11,700 $260,000
% decrease 1994–2009 57% 70% 56%for admission have not changed, total days spent in hospital for
all reasons have declined from 1753 in 1994, to 1855 in 2000,
1285 in 2005, 1130 in 2008 and 991 days in 2009. Patients with
chronic Psa accounted for 990 hospital days in 1994, 980 days
in 2000, 550 days in 2005, 290 days in 2008 and 241 days in
2009. In 2008 the majority of the chronic Pseudomonas patient
hospital days (225 days) were due to 4 patients, 2 of whom were
being assessed for lung transplant and required several hospital
admissions during the year. In 2009 Psa eradication protocol
admissions accounted for 134 hospital days (13% of total
hospital days) in 10 patients.
The cost from total hospital days for all CF related
admissions (Table 4) declined from $3.85 million CAD inhospital day utilization.
Hospital days for Pseudomonas
eradication protocols
(% of total hospital days)
Total Psa-related
hospital days
Total hospital
days
None 990 1753
130 (7%) 1110 1855
168 (13%) 718 1285
330 (29%) 620 1130
134 (13%) 375 991
$ Nebulised antibiotics
for eradication 6 month
treatment protocol (at home)
$ Total nebulised
antibiotic cost
$Total IV and
nebulised antibiotic
cost
– $639,000 $733,000
$100,000 $371,700 $411,700
– 42% 44%
Table 4
Hospital utilization costs based on an estimated average cost of $2200 CADa/
day.
Year Cost for all CF admissions
(average cost of
$2200 CADa/day)
Cost for pulmonary exacerbations
related to chronic Pseudomonas
infection (average cost of $2200
CADa/day)
1994 $3.85 million (1753 days) $2.17 million (990 days)
2000 $4.08 million (1855 days) $2.15 million (980 days)
2005 $2.83 million (1285 days) $1.21 million (550 days)
2008 $2.48 million (1130 days) $638,000 (290 days)
2009 $2.18 million (991 days) $530,200 (241 days)
% decrease
1994–2009
43% 75%
a Based on 1994 daily hospital bed cost.
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decrease. Those hospital bed costs for pulmonary exacerbations
in patients with chronic Pseudomonas infection reduced from
$2.17 million in 1994 to $530,200 in 2009.
Similarly, the in-hospital IV anti-pseudomonal antibiotic use
declined from approximately $94,000 a year in 1994 to $40,000 a
year in 2009 (this includes both the cost of IV eradication protocol
treatments and treatments for pulmonary exacerbations due to
chronic Psa infection). In-hospital use of nebulised colistimethate
for patients with chronic Psa also decreased from approximately
$39,000 per year in 1994 to $11,700 per year in 2009.
Costs for home nebulised antibiotics also decreased, with 19
patients receiving either nebulised colistimethate or TOBI® for
chronic Psa in 2009 at a cost of approximately $260,000 per
year. Home use of nebulised colistimethate for 6 months as per
our eradication protocol came to a cost of $100,000 in 2009.
The total cost for home nebulised antibiotics for both chronic
Psa and Psa eradication protocols was $360,000 in 2009. This
compares to a home antibiotic aerosol cost of $600,000 in 1994
for chronic Psa alone (Table 3). (28 day cost of TOBI®=$2835
CAD, 28 day cost of colistimethate=$1156 CAD).Table 5
Pulmonary function and chronic Psa infection for 18 yr old patients at time of
Graduation to the Adult CF Clinic 2005–2009.
Outcome 2005 2006 2007 2008 2009
Number of graduates 6 12 13 13 8
Mean FEV1 % predicted 77 76.2 78.8 89.3 94.1
Psa culture positive (%) 50 66 46.6 39.5 12.5
FEV1, forced expiratory volume in 1 s.4. Discussion
Over a 15 year period of close surveillance for the appearance
of P. aeruginosa, this protocol for the first appearance of Psa and
repeat treatments upon the reappearance of Psa has decreased the
prevalence and delayed the establishment of chronicPsa infection
in our paediatric clinic. Eradication treatment courses were well
tolerated, and provided an opportunity to optimize nutritional
support, provide physiotherapy review and supervision, and
reinforce adherence. This was a retrospective review and
therefore patient questionnaires or QOL data was not available.
During this reporting period, the clinic population's
acceptance of this treatment protocol was noteworthy in an
era when early eradication of Psa was not yet considered
standard of care for CF. Patients and families were given a full
explanation of the rationale of the protocol, and notified that
success could not be guaranteed. Over time, however, the
success of the protocol became an accepted norm for the clinic.In addition to its putative effects on improved life expectancy,
quality of life, and maintenance of pulmonary function, this Psa
eradication protocol has had an impact on hospital bed utilization
and use of IV and nebulised anti-Psa antibiotics. Intravenous and
aerosol antibiotic costs during hospital admission are borne by
Canada's universal health care system.However, the cost of home
use for these medications must be borne by families with varying
degrees of support from “pharmacare” or other insurance plans.
Overall, therefore, the decrease in costs observed is of benefit to
both public funding agencies and to families, and is one of the
factors contributing to the continued acceptance of this protocol
by clinic families.
The long term effect on the prevalence of chronic Psa
infection among CF patients depends on the overall efficacy of
the eradication regime employed. The clearance rate of 90% for
all patients, and 96% for patients only infected with a classic
(non-mucoid) strain of Psa is reflected in the decrease in the
overall prevalence of Psa infection in the entire clinic from 44%
in 1994 to 15% in 2009. In the 2008 Canadian Cystic Fibrosis
Patient Data Registry (CPDR) [17] the prevalence of
P. aeruginosa in 11–17 years old patients is 40%, compared to
18.7% in that same cohort of patients in our CF clinic. Similarly,
pulmonary function is maintained when there is less chronic Psa
infection as shown in the cohort of 18 year old patients
graduating to our colleagues at the Adult CF Clinic (Table 5).
Other protocols not requiring IV antibiotics for the initial
stage have been described but insufficient data have yet to be
reported with which to compare long-term results. Different
regimens may be better suited for specific population groups;
for example outpatient nebulised antibiotic regimens for adults
not able to take time away from work; or newborns identified by
Newborn Screening Programs with close surveillance of
cultures for the first appearance of Psa. Psa antibody and/or
Psa RAPD type guided eradication protocols may assist in
optimizing efficacy and long term outcome. The ELITE trial has
reported a 92% clearance rate for Psa in 88 of 123 CF anti-Psa
antibody negative patients 1 month after treatment with inhaled
TOBI [13]. This trial represents a far less intensive initial
treatment regimen and reduced burden to patients and families.
However, if the ELITE results had been analysed on an intent-
to-treat basis for all 123 patients enrolled, presumably the
results would be less satisfactory.
In this report, we have presented the long term results of a
review of costs associated with Psa acquisition in CF. Results
indicate that application of our eradication protocol over a
15 year period has had economic and resource utilization
benefits in addition to clinical results. This was a retrospective
study with no control or comparator group and therefore
180 Y.P. Lillquist et al. / Journal of Cystic Fibrosis 10 (2011) 175–180interpretation of the data is site specific. Future development of
more effective protocols is desirable as it impacts the long term
prevalence of P. aeruginosa and the subsequent cost of drug
and hospital bed utilization as well as the clinical status of CF
patients.
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